Alterity Therapeutics to Present New Data on ATH434 at the :

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...

Related Keywords

Colorado , United States , Melbourne , Victoria , Australia , Boston , Massachusetts , San Francisco , California , Denver , American , Americans , Remy Bernarda , Danielo Claassen , Margaret Bradbury , David Stamler , Daniel Claassen , Hannah Howlett , Department Of Pharmaceutical Sciences , Nonclinical Development , European Commission , Alterity Therapeutics , Nasdaq , World Orphan Drug Congress United States , American Academy Of Neurology , Wayne State University , National Institute Of Health , Vanderbilt University Medical Center , Parkinson Foundation , Unique Iron Targeting Drug , Treating Friedreich , Pharmaceutical Sciences , Wayne State , American Academy , Novel Inhibitor , Synuclein Aggregation , Multiple System Atrophy , Chief Executive Officer , Plight Chain , Clinical Progression , Early Multiple System , Vanderbilt University Medical , Clinical Phase Small Molecule , Moderate Affinity , Disease Model , Vice President , System Atrophy , Mouse Model , National Institute , Neurological Disorders , Disease Information Page , Multiple System , Media Contacts , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Conference , Preclinical Research ,